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Bcl2/Bax ratios in chronic lymphocytic leukaemia and
their correlation with in vitro apoptosis and clinical
resistance
Sir,
We were interested to read the recent article by Pepper et al (Br J
Cancer 76: 935-938, 1997). This paper discussed flow cytometric
quantitation of apoptosis as a measure of responsiveness to
chemotherapy in B-cell chronic lymphocytic leukaemia (B-CLL),
with particular reference to Bcl-2/Bax protein ratios. Our group,
using the same antibodies, is pursuing very similar research in
superficial bladder cancer. We have compared percentages ofposi-
tively staining Bcl-2 and Bax tumour cells before and after in vitro
exposure to mitomycin C in bladder tumours. We have obtained
results (unpublished) which would further support the theory that
Bax dysregulation plays an important role in chemoresistant
tumours (Boersma et al, 1997; Chresta et al, 1996).
As the next stage to our own experiments, we would be very
keen to investigate co-expression of Bcl-2 and Bax in the
bladder tumour cells using flow cytometry. Co-expression
would indicate the extent of heterodimerization of Bcl-2 with
Bax that is likely to affect the inhibition of apoptosis after
chemotherapy (Yang et al, 1995). We were therefore very inter-
ested to read the authors' description of a triple-colour flow
cytometry methodology in B-CLL cells. They described how
they sequentially incubated the cells with anti-CD19 Cy5 PE-
conjugated antibody, Bcl-2 FITC and Bax followed by PE-
labelled secondary antibody. Unfortunately, the authors did not
report their findings on the co-expression of Bcl-2 and Bax in the
B-CLL cells.
Secondly, the paper did not report the Bcl-2 and Bax protein
levels in their clinically untreated patient samples after in vitro
exposure to chlorambucil. Considering our own findings, which
showed a correlation between apoptotic index > 10% and
increased Bax protein, these data would have been very relevant.
Thirdly, we were confused by the fact that the authors confirmed
that the Annexin V-positive Iymphocytes cells were apoptotic by
morphological assessment. Annexin V binds to cells in the early
stages ofapoptosis, are not all likely to exhibit the classical features
of apoptosis (Martin et al, 1995). It would be interesting to know
what criteria the authors used to confirm that the Annexin V-posi-
tive lymphocytes were or were not in early apoptosis.
In summary, the authors designed an important study, but unfor-
tunately they did not exploit or report all oftheir data.
KE Williamson', JD Kelly2, PWHamilton', D McManus'
and SR Johnston2
Departments of'Pathology and2Surgery; The Queen's University
ofBelfast, Northern Ireland, UK
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Bcl2/Bax ratios in chronic lymphocytic leukaemia and
their correlation with in vitro apoptosis and clinical
responsiveness - reply
Sir,
The quantification of Bcl-2 and Bax proteins was achieved by
triple-colour analysis as described in our paper, and the co-expres-
sion of Bcl-2 and Bax was measured in these experiments.
However, our data relate to protein expression in the total gated
B-lymphocyte population of cells rather than to individual cell
analysis; all gated cells expressed both Bcl-2 and Bax proteins.
The index we used to describe this co-expression was a ratio ofthe
two proteins (Bcl-2/Bax) as there is evidence that the ratio ofdeath
promoters to death inhibitors within the cell may determine
susceptibility to death signals (Korsmeyer et al, 1993; Thomas
et al, 1996; Pepper et al, 1996). These ratios were calculated as
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follows. The mean fluorescent intensity (MFI) was calculated for
each protein using WinMDI software (J Trotter, Scripps Research
Institute, USA) and these values were then converted to molecules
of equivalent soluble fluorochrome (MESF) using a calibration
curve to standardize the data. The calibration curve was
constructed by operating the flow cytometer under identical condi-
tions and monitoring a mixture of beads labelled with known
amounts of fluorochrome. In this way, day-to-day variation in
fluorescence detection are controlled for, and, in addition, differ-
ences in fluorescent intensity between FITC and PE can be
normalized. Obviously we would be willing for Williamson et al
to have a copy ofthe raw data derived from these experiments and
would also refer them to our publication in the British Journal of
Haematology (1996).
The Bcl-2 and Bax protein expression presented in this paper
relate to the total population of cells, regardless of their status in
terms ofresponse to apoptotic signals, i.e. no attempt was made to
gate viable and non-viable cells. However, we agree that it is of
interest to measure Bcl-2 and Bax protein levels both before and
after exposure to drug. This indeed is the subject of our latest
publication in Leukemia & Lymphoma (1998). Briefly, our results
indicate that Bcl-2 and Bax protein levels are significantly
different in those cells that resist apoptosis when compared with
those that do not, and this difference is particularly pronounced in
terms ofBax protein expression.
In the Annexin V positivity experiments we used Annexin V as
a measure of apoptosis. It is true that Annexin V is capable of
labelling very early-stage apoptotic cells that have not yet under-
gone morphological changes. However, we would point out that in
these experiments we labelled our cells with Annexin V after incu-
bation with drug for 48 h and most of the cells that were under-
going apoptosis were in fact late-stage apoptotic cells that were
easily identified morphologically by membrane blebbing, chro-
matin condensation and general cellular shrinkage. Recent data
from our laboratory have confirmed that morphological evidence
ofapoptosis can be seen as early as 16 h after drug exposure but is
much more marked after 24 h (unpublished).
P Bentley, C Pepper and THoy
Llandough Hospital, Penlan Rd, Penarth CF 64 2XX, UK
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Insulin-like growth factor I in relation to prostate
cancer and benign prostatic hyperplasia
Sir,
We were interested to read the paper by Mantzoros et al (1997)
claiming that serum insulin-like growth factor 1 (IGF-1) levels
were elevated in prostate cancer patients and suggesting that serum
IGF-1 may represent an independent risk factor for this disease.
This is in marked contrast to our data demonstrating that serum
IGF-I and IGF-2 levels were not different in patients with prostate
cancer relative to age-matched controls (Cohen et al, 1993).
Similarly, Ho and Baxter (1997) found normal IGF-1 levels in the
sera of patients with prostate cancer. The IGFs circulate
complexed to a family of proteins known as the IGF-binding
proteins (IGFBPs), as reviewed by Daughaday et al (1986).
Apparently, unknown to these authors, IGFBPs have been shown
to interfere with radioimmunoassays (RIAs) ofthe IGFs as a result
oftheir ability to bind to the labelled IGF trace and to artifactually
elevate the readings of IGF levels, as reviewed by Rosenfeld and
Gargosky (1996). While various methods have been used to
attempt to remove the IGFBPs from the IGFs before assay, only
techniques involving acidification followed by chromatography
have been demonstrated by Bang et al (1991) to successfully
perform this separation. RIAs, such as the Nichols kit used by
Mantzoros et al (1997), use an ethanol extraction method which,
while able to remove most of the IGFBP-3 found as the 150-kDa
complex ofthe IGFs, are completely ineffectual in removing other
IGFBPs in serum including IGFBP-2 and IGFBP-4, as shown by
Frey et al (1994). In our report (Cohen et al, 1993), we have shown
a two- to threefold elevation in IGFBP-2 levels in the sera of
patients with prostate cancer as assayed by both RIA and Western
ligand blotting. We have since verified that observation on a
second cohort ofpatients and, in addition, we have demonstrated a
more moderate elevation of IGFBP-2 levels in the sera ofpatients
with benign prostatic hyperplasia. We have also recently found a
twofold elevation in the serum levels of IGFBP-4 in the sera of
prostate cancer patients. Our findings of elevated IGFBP-2 in
prostate cancer patients have also been replicated by Kanety et al
(1993) and Ho and Baxter (1997). As IGFBP-2 and IGFBP-4 are
not removed by the ethanol extraction method used by Mantzoros
et al (1997), we believe that their patients actually had normal
serum IGF-1 levels, but elevated serum IGFBP-2 and IGFBP-4
levels, leading to an artifactual elevation in the IGF-1 RIA reading.
This situation is similar to a report in the New EnglandJournal of
Medicine by Pintor et al (1989), allegedly discovering a child with
phenotypic Laron dwarfism but with normal IGF-1 levels (which
are dramatically reduced in that condition). Those authors used the
exact same Nichols IGF-1 RIA kit to measure IGF-1 levels in the
serum oftheir subject as Mantzoros et al (1997) did in their paper.
Alerted to the possibility ofan artifact by a letter to the editor from
Laron and Silbergeld (1989), the authors re-assayed their child's
serum IGF-1 with an acid-chromatography technique and discov-
ered it to be undetectable, leading them to issue a retraction oftheir
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